It remains to be demonstrated if simultaneous utilization of antibodies directed against mesothelin, CD44 and β-1 integrins will substantially inhibit binding of ovarian tumor cells to the mesothelium. The gene discussed is MSLN; the disease is ovarian neoplasm.